Identifying hemophilia B carriers: Utility of aPTT, factor IX levels and ratios of factor IX to other Vitamin K dependent factors

Introduction Diagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a family history of hemophilia, diagnosing HB carrier status is challenging. Genetic testing is the gold‐standard, however it is reserved for i...

Full description

Saved in:
Bibliographic Details
Published inHaemophilia : the official journal of the World Federation of Hemophilia Vol. 30; no. 4; pp. 1003 - 1009
Main Authors Shu, Michael, Malcolmson, Caroline, Bosch, Alessandra, Markovic, Teodora, Wakefield, Cindy, Bouskill, Vanessa, Carcao, Manuel
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.07.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Introduction Diagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a family history of hemophilia, diagnosing HB carrier status is challenging. Genetic testing is the gold‐standard, however it is reserved for individuals with a high suspicion of carrier status. Aims To describe the distribution of activated partial thromboplastin time (aPTT) and factor IX coagulant (FIX:C) levels in HB carriers and assess the ratio of FIX:C to other Vitamin K dependent factors (FII:C, FVII:C, FX:C) as an indicator of HB carrier status. Methods In this retrospective, single‐centre cohort study, subjects were included if they were obligate or genetically proven HB carriers. Distributions of aPTT and FIX:C were described and the relationship between FIX:C levels in carriers and severity of familial HB was analysed. Ratios of FIX:C to FII:C, FVII:C, FX:C were calculated. Results Seventy‐two female HB carriers (median age: 34 years; IQR 24–43) were included. Median aPTT and FIX:C levels were 33.0 s [IQR 30.0–37.0] and 57 IU/dL [IQR 43–74]. Fifteen carriers (21%) had mild HB (FIX:C levels of 10–40 IU/dL). FIX:C levels trended higher in carriers of mild HB versus carriers of moderate/severe HB. In six carriers, the median ratio of FIX:C to other Vitamin K dependent factors was 0.44, with 92% of ratios being ≤ 0.75. Conclusion aPTT and FIX:C levels were unreliable in diagnosing HB carrier status. A low ratio of FIX:C to other Vitamin K dependent factors may be a useful marker of HB carrier status.
AbstractList Diagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a family history of hemophilia, diagnosing HB carrier status is challenging. Genetic testing is the gold-standard, however it is reserved for individuals with a high suspicion of carrier status. To describe the distribution of activated partial thromboplastin time (aPTT) and factor IX coagulant (FIX:C) levels in HB carriers and assess the ratio of FIX:C to other Vitamin K dependent factors (FII:C, FVII:C, FX:C) as an indicator of HB carrier status. In this retrospective, single-centre cohort study, subjects were included if they were obligate or genetically proven HB carriers. Distributions of aPTT and FIX:C were described and the relationship between FIX:C levels in carriers and severity of familial HB was analysed. Ratios of FIX:C to FII:C, FVII:C, FX:C were calculated. Seventy-two female HB carriers (median age: 34 years; IQR 24-43) were included. Median aPTT and FIX:C levels were 33.0 s [IQR 30.0-37.0] and 57 IU/dL [IQR 43-74]. Fifteen carriers (21%) had mild HB (FIX:C levels of 10-40 IU/dL). FIX:C levels trended higher in carriers of mild HB versus carriers of moderate/severe HB. In six carriers, the median ratio of FIX:C to other Vitamin K dependent factors was 0.44, with 92% of ratios being ≤ 0.75. aPTT and FIX:C levels were unreliable in diagnosing HB carrier status. A low ratio of FIX:C to other Vitamin K dependent factors may be a useful marker of HB carrier status.
Introduction Diagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a family history of hemophilia, diagnosing HB carrier status is challenging. Genetic testing is the gold‐standard, however it is reserved for individuals with a high suspicion of carrier status. Aims To describe the distribution of activated partial thromboplastin time (aPTT) and factor IX coagulant (FIX:C) levels in HB carriers and assess the ratio of FIX:C to other Vitamin K dependent factors (FII:C, FVII:C, FX:C) as an indicator of HB carrier status. Methods In this retrospective, single‐centre cohort study, subjects were included if they were obligate or genetically proven HB carriers. Distributions of aPTT and FIX:C were described and the relationship between FIX:C levels in carriers and severity of familial HB was analysed. Ratios of FIX:C to FII:C, FVII:C, FX:C were calculated. Results Seventy‐two female HB carriers (median age: 34 years; IQR 24–43) were included. Median aPTT and FIX:C levels were 33.0 s [IQR 30.0–37.0] and 57 IU/dL [IQR 43–74]. Fifteen carriers (21%) had mild HB (FIX:C levels of 10–40 IU/dL). FIX:C levels trended higher in carriers of mild HB versus carriers of moderate/severe HB. In six carriers, the median ratio of FIX:C to other Vitamin K dependent factors was 0.44, with 92% of ratios being ≤ 0.75. Conclusion aPTT and FIX:C levels were unreliable in diagnosing HB carrier status. A low ratio of FIX:C to other Vitamin K dependent factors may be a useful marker of HB carrier status.
Diagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a family history of hemophilia, diagnosing HB carrier status is challenging. Genetic testing is the gold-standard, however it is reserved for individuals with a high suspicion of carrier status.INTRODUCTIONDiagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a family history of hemophilia, diagnosing HB carrier status is challenging. Genetic testing is the gold-standard, however it is reserved for individuals with a high suspicion of carrier status.To describe the distribution of activated partial thromboplastin time (aPTT) and factor IX coagulant (FIX:C) levels in HB carriers and assess the ratio of FIX:C to other Vitamin K dependent factors (FII:C, FVII:C, FX:C) as an indicator of HB carrier status.AIMSTo describe the distribution of activated partial thromboplastin time (aPTT) and factor IX coagulant (FIX:C) levels in HB carriers and assess the ratio of FIX:C to other Vitamin K dependent factors (FII:C, FVII:C, FX:C) as an indicator of HB carrier status.In this retrospective, single-centre cohort study, subjects were included if they were obligate or genetically proven HB carriers. Distributions of aPTT and FIX:C were described and the relationship between FIX:C levels in carriers and severity of familial HB was analysed. Ratios of FIX:C to FII:C, FVII:C, FX:C were calculated.METHODSIn this retrospective, single-centre cohort study, subjects were included if they were obligate or genetically proven HB carriers. Distributions of aPTT and FIX:C were described and the relationship between FIX:C levels in carriers and severity of familial HB was analysed. Ratios of FIX:C to FII:C, FVII:C, FX:C were calculated.Seventy-two female HB carriers (median age: 34 years; IQR 24-43) were included. Median aPTT and FIX:C levels were 33.0 s [IQR 30.0-37.0] and 57 IU/dL [IQR 43-74]. Fifteen carriers (21%) had mild HB (FIX:C levels of 10-40 IU/dL). FIX:C levels trended higher in carriers of mild HB versus carriers of moderate/severe HB. In six carriers, the median ratio of FIX:C to other Vitamin K dependent factors was 0.44, with 92% of ratios being ≤ 0.75.RESULTSSeventy-two female HB carriers (median age: 34 years; IQR 24-43) were included. Median aPTT and FIX:C levels were 33.0 s [IQR 30.0-37.0] and 57 IU/dL [IQR 43-74]. Fifteen carriers (21%) had mild HB (FIX:C levels of 10-40 IU/dL). FIX:C levels trended higher in carriers of mild HB versus carriers of moderate/severe HB. In six carriers, the median ratio of FIX:C to other Vitamin K dependent factors was 0.44, with 92% of ratios being ≤ 0.75.aPTT and FIX:C levels were unreliable in diagnosing HB carrier status. A low ratio of FIX:C to other Vitamin K dependent factors may be a useful marker of HB carrier status.CONCLUSIONaPTT and FIX:C levels were unreliable in diagnosing HB carrier status. A low ratio of FIX:C to other Vitamin K dependent factors may be a useful marker of HB carrier status.
IntroductionDiagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a family history of hemophilia, diagnosing HB carrier status is challenging. Genetic testing is the gold‐standard, however it is reserved for individuals with a high suspicion of carrier status.AimsTo describe the distribution of activated partial thromboplastin time (aPTT) and factor IX coagulant (FIX:C) levels in HB carriers and assess the ratio of FIX:C to other Vitamin K dependent factors (FII:C, FVII:C, FX:C) as an indicator of HB carrier status.MethodsIn this retrospective, single‐centre cohort study, subjects were included if they were obligate or genetically proven HB carriers. Distributions of aPTT and FIX:C were described and the relationship between FIX:C levels in carriers and severity of familial HB was analysed. Ratios of FIX:C to FII:C, FVII:C, FX:C were calculated.ResultsSeventy‐two female HB carriers (median age: 34 years; IQR 24–43) were included. Median aPTT and FIX:C levels were 33.0 s [IQR 30.0–37.0] and 57 IU/dL [IQR 43–74]. Fifteen carriers (21%) had mild HB (FIX:C levels of 10–40 IU/dL). FIX:C levels trended higher in carriers of mild HB versus carriers of moderate/severe HB. In six carriers, the median ratio of FIX:C to other Vitamin K dependent factors was 0.44, with 92% of ratios being ≤ 0.75.ConclusionaPTT and FIX:C levels were unreliable in diagnosing HB carrier status. A low ratio of FIX:C to other Vitamin K dependent factors may be a useful marker of HB carrier status.
Author Bosch, Alessandra
Markovic, Teodora
Shu, Michael
Carcao, Manuel
Bouskill, Vanessa
Malcolmson, Caroline
Wakefield, Cindy
Author_xml – sequence: 1
  givenname: Michael
  orcidid: 0000-0003-1940-3734
  surname: Shu
  fullname: Shu, Michael
  organization: The Hospital for Sick Children
– sequence: 2
  givenname: Caroline
  orcidid: 0000-0002-3916-7022
  surname: Malcolmson
  fullname: Malcolmson, Caroline
  email: caroline.malcolmson@sickkids.ca
  organization: The Hospital for Sick Children
– sequence: 3
  givenname: Alessandra
  surname: Bosch
  fullname: Bosch, Alessandra
  organization: The Hospital for Sick Children
– sequence: 4
  givenname: Teodora
  surname: Markovic
  fullname: Markovic, Teodora
  organization: The Hospital for Sick Children
– sequence: 5
  givenname: Cindy
  surname: Wakefield
  fullname: Wakefield, Cindy
  organization: The Hospital for Sick Children
– sequence: 6
  givenname: Vanessa
  orcidid: 0000-0003-3011-6445
  surname: Bouskill
  fullname: Bouskill, Vanessa
  organization: The Hospital for Sick Children
– sequence: 7
  givenname: Manuel
  orcidid: 0000-0001-5350-1763
  surname: Carcao
  fullname: Carcao, Manuel
  organization: The Hospital for Sick Children
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38924261$$D View this record in MEDLINE/PubMed
BookMark eNp1kV9vFCEUxYmpsX_0wS9gSHyxidPCMMMwvtWm2o1N9GE1vpG7zMWlmYEtsDb76DeXdbcxaZQXCPzOueScY3Lgg0dCXnJ2xss6XwKe8ZZJ9YQccSHbqm65PNieW16pmstDcpzSLWNc1Ew-I4dC9XVTS35Efs0G9NnZjfM_6BKnsFq60QF9Tw3E6DCmd_RrLld5Q4Ol8GU-f0stmBwinX2nI_7EMVHwA42QXUhb6O9zDjTkJUb6zWWYnKef6IAr9NuZeyw9J08tjAlf7PcTMv9wNb-8rm4-f5xdXtxURrRCVWaAFhR02FrorIKFHcC0EtEY2wtRK971rOPc1F0vUVkObKgZCmmVbbqFOCFvdrarGO7WmLKeXDI4juAxrJMWrCvKXqqmoK8fobdhHX35XKEUb1TDWlmoV3tqvZhw0KvoJogb_ZBtAc53gIkhpYhWm5JCCcnnCG7UnOlte7q0p_-0VxSnjxQPpv9i9-73bsTN_0F9fXG1U_wG9vmolg
CitedBy_id crossref_primary_10_1177_01939459251325490
Cites_doi 10.1111/hae.14232
10.1111/jth.15397
10.1111/hae.14094
10.1111/j.1538-7836.2012.04653.x
10.1016/B978-0-12-815499-1.00026-0
10.1182/blood-2005-09-3879
10.1002/ajmg.1320260313
10.1097/MBC.0000000000000083
10.1046/j.1365-2141.1999.01631.x
10.1002/rth2.12783
10.3402/fnr.v56i0.5329
10.1111/hae.14046
10.1111/j.1537-2995.2010.02604.x
10.1111/hae.13089
10.1111/jth.15301
10.1055/s-0032-1326786
10.1002/ajh.24709
10.1097/MPH.0000000000000022
10.1111/jth.13294
10.1177/1076029611422364
10.1159/isbn.978-3-318-02198-1
10.1111/hae.13376
10.1111/j.1365-2516.2006.01397.x
10.1111/cge.12709
ContentType Journal Article
Copyright 2024 The Author(s). published by John Wiley & Sons Ltd.
2024 The Author(s). Haemophilia published by John Wiley & Sons Ltd.
2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024 The Author(s). published by John Wiley & Sons Ltd.
– notice: 2024 The Author(s). Haemophilia published by John Wiley & Sons Ltd.
– notice: 2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
7T5
8FD
FR3
H94
K9.
P64
RC3
7X8
DOI 10.1111/hae.15068
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
Immunology Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Genetics Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Genetics Abstracts
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1365-2516
EndPage 1009
ExternalDocumentID 38924261
10_1111_hae_15068
HAE15068
Genre article
Journal Article
GrantInformation_xml – fundername: Canadian Pediatric Thrombosis and Hemostasis Network
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OB
1OC
24P
29I
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHEFC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EGARE
EJD
EMB
EMK
EMOBN
EPT
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
NPM
7T5
8FD
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
FR3
H94
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c3538-cda5a8a7e5fa7f8abfdac56eeccf933281790711c2796e8f1a0d20e36f8f47b3
IEDL.DBID DR2
ISSN 1351-8216
1365-2516
IngestDate Fri Jul 11 09:36:51 EDT 2025
Fri Jul 25 10:07:35 EDT 2025
Wed Feb 19 02:06:35 EST 2025
Thu Apr 24 22:50:37 EDT 2025
Tue Jul 01 05:10:53 EDT 2025
Wed Jan 22 17:17:43 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords blood coagulation factors
factor IX
genetic carrier screening
activated partial thromboplastin time
hemophilia B
Language English
License Attribution-NonCommercial-NoDerivs
2024 The Author(s). Haemophilia published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3538-cda5a8a7e5fa7f8abfdac56eeccf933281790711c2796e8f1a0d20e36f8f47b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-3011-6445
0000-0003-1940-3734
0000-0001-5350-1763
0000-0002-3916-7022
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhae.15068
PMID 38924261
PQID 3081484056
PQPubID 2045152
PageCount 7
ParticipantIDs proquest_miscellaneous_3072799684
proquest_journals_3081484056
pubmed_primary_38924261
crossref_citationtrail_10_1111_hae_15068
crossref_primary_10_1111_hae_15068
wiley_primary_10_1111_hae_15068_HAE15068
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate July 2024
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: July 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Chichester
PublicationTitle Haemophilia : the official journal of the World Federation of Hemophilia
PublicationTitleAlternate Haemophilia
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2021; 27
2006; 108
2017; 92
2016; 90
2022; 6
2020
2021; 19
2014; 36
2014; 25
2020; 26
2012; 18
2012; 38
2013
1996; 58
1999; 106
2012; 56
2007; 13
2016; 14
2012; 10
1987; 26
2010; 50
2016; 22
2018; 24
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
Becker J (e_1_2_10_8_1) 1996; 58
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_11_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 106
  start-page: 870
  issue: 4
  year: 1999
  end-page: 874
  article-title: Origin of mutation in sporadic cases of haemophilia A
  publication-title: Br J Haematol
– volume: 22
  start-page: 912
  issue: 6
  year: 2016
  end-page: 918
  article-title: Evaluation of the utility of the ISTH‐BAT in haemophilia carriers: a multinational study
  publication-title: Haemophilia
– volume: 26
  start-page: 1
  issue: 6
  year: 2020
  end-page: 158
  article-title: WFH guidelines for the management of hemophilia, 3rd edition
  publication-title: Haemophilia
– volume: 24
  start-page: 180
  issue: 2
  year: 2018
  end-page: 185
  article-title: The spectrum of bleeding in women and girls with haemophilia B
  publication-title: Haemophilia
– volume: 14
  start-page: 953
  issue: 5
  year: 2016
  end-page: 963
  article-title: Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms
  publication-title: J Thromb Haemost
– volume: 90
  start-page: 63
  issue: 1
  year: 2016
  end-page: 68
  article-title: Origin of mutation in sporadic cases of severe haemophilia A in Sweden
  publication-title: Clin Genet
– volume: 38
  start-page: 727
  issue: 7
  year: 2012
  end-page: 734
  article-title: The diagnosis and management of congenital hemophilia
  publication-title: Semin Thromb Hemost
– volume: 19
  start-page: 1883
  issue: 8
  year: 2021
  end-page: 1887
  article-title: A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH
  publication-title: J Thromb Haemost
– volume: 27
  start-page: 293
  issue: 2
  year: 2021
  end-page: 304
  article-title: Women and girls with haemophilia and bleeding tendencies: outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review
  publication-title: Haemophilia
– volume: 58
  start-page: 657
  issue: 4
  year: 1996
  end-page: 670
  article-title: Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type‐dependent sex ratio of mutation frequencies
  publication-title: Am J Hum Genet
– volume: 13
  start-page: 90
  issue: 1
  year: 2007
  end-page: 92
  article-title: Prevalence of sporadic and familial haemophilia
  publication-title: Haemophilia
– volume: 50
  start-page: 1571
  issue: 7
  year: 2010
  end-page: 1580
  article-title: Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents
  publication-title: Transfusion
– volume: 26
  start-page: 591
  issue: 3
  year: 1987
  end-page: 598
  article-title: Reproductive choices in hemophilic men and carriers
  publication-title: Am J Med Genet
– volume: 10
  start-page: 615
  issue: 4
  year: 2012
  end-page: 621
  article-title: Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders
  publication-title: J Thromb Haemost
– volume: 108
  start-page: 52
  issue: 1
  year: 2006
  end-page: 56
  article-title: Bleeding in carriers of hemophilia
  publication-title: Blood
– volume: 19
  start-page: 1493
  issue: 6
  year: 2021
  end-page: 1505
  article-title: Genetic analysis of carrier status in female members of Japanese hemophilia families
  publication-title: J Thromb Haemost
– start-page: 445
  year: 2020
  end-page: 467
– volume: 92
  start-page: E94
  issue: 6
  year: 2017
  end-page: E96
  article-title: Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A
  publication-title: Am J Hematol
– volume: 56
  year: 2012
  article-title: Vitamin K: the effect on health beyond coagulation—an overview
  publication-title: Food Nutr Res
– volume: 6
  issue: 6
  year: 2022
  article-title: Challenges and knowledge gaps facing hemophilia carriers today: perspectives from patients and health care providers
  publication-title: Res Pract Thromb Haemost
– volume: 27
  start-page: 75
  issue: 3
  year: 2021
  end-page: 81
  article-title: Women and girls with haemophilia: lessons learned
  publication-title: Haemophilia
– volume: 18
  start-page: 316
  issue: 3
  year: 2012
  end-page: 319
  article-title: The influence of the ABO blood type on the distribution of von Willebrand factor in healthy children with no bleeding symptoms
  publication-title: Clin Appl Thromb Hemost
– volume: 36
  start-page: e224
  issue: 4
  year: 2014
  end-page: e230
  article-title: Both hemophilia health care providers and hemophilia a carriers report that carriers have excessive bleeding
  publication-title: J Pediatr Hematol Oncol
– volume: 25
  start-page: 471
  issue: 5
  year: 2014
  end-page: 475
  article-title: Clotting factor level is not a good predictor of bleeding in carriers of haemophilia A and B
  publication-title: Blood Coagul Fibrinolysis
– year: 2013
– ident: e_1_2_10_5_1
  doi: 10.1111/hae.14232
– ident: e_1_2_10_16_1
  doi: 10.1111/jth.15397
– ident: e_1_2_10_7_1
  doi: 10.1111/hae.14094
– ident: e_1_2_10_26_1
  doi: 10.1111/j.1538-7836.2012.04653.x
– ident: e_1_2_10_14_1
  doi: 10.1016/B978-0-12-815499-1.00026-0
– ident: e_1_2_10_17_1
  doi: 10.1182/blood-2005-09-3879
– ident: e_1_2_10_13_1
  doi: 10.1002/ajmg.1320260313
– ident: e_1_2_10_18_1
  doi: 10.1097/MBC.0000000000000083
– ident: e_1_2_10_11_1
  doi: 10.1046/j.1365-2141.1999.01631.x
– ident: e_1_2_10_3_1
  doi: 10.1002/rth2.12783
– ident: e_1_2_10_24_1
  doi: 10.3402/fnr.v56i0.5329
– ident: e_1_2_10_25_1
  doi: 10.1111/hae.14046
– ident: e_1_2_10_23_1
  doi: 10.1111/j.1537-2995.2010.02604.x
– ident: e_1_2_10_4_1
  doi: 10.1111/hae.13089
– ident: e_1_2_10_19_1
  doi: 10.1111/jth.15301
– ident: e_1_2_10_2_1
  doi: 10.1055/s-0032-1326786
– ident: e_1_2_10_10_1
  doi: 10.1002/ajh.24709
– ident: e_1_2_10_15_1
  doi: 10.1097/MPH.0000000000000022
– ident: e_1_2_10_22_1
  doi: 10.1111/jth.13294
– ident: e_1_2_10_21_1
  doi: 10.1177/1076029611422364
– volume: 58
  start-page: 657
  issue: 4
  year: 1996
  ident: e_1_2_10_8_1
  article-title: Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type‐dependent sex ratio of mutation frequencies
  publication-title: Am J Hum Genet
– ident: e_1_2_10_20_1
  doi: 10.1159/isbn.978-3-318-02198-1
– ident: e_1_2_10_6_1
  doi: 10.1111/hae.13376
– ident: e_1_2_10_9_1
  doi: 10.1111/j.1365-2516.2006.01397.x
– ident: e_1_2_10_12_1
  doi: 10.1111/cge.12709
SSID ssj0013206
Score 2.4070122
Snippet Introduction Diagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a...
Diagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a family...
IntroductionDiagnosing hemophilia B (HB) carrier status is important to manage bleeding in carriers and to prevent bleeding in potential offspring. Without a...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1003
SubjectTerms activated partial thromboplastin time
Bleeding
blood coagulation factors
Coagulation factors
factor IX
Factor IX deficiency
genetic carrier screening
Hemophilia
hemophilia B
Ratios
Thromboplastin
Vitamin K
Title Identifying hemophilia B carriers: Utility of aPTT, factor IX levels and ratios of factor IX to other Vitamin K dependent factors
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhae.15068
https://www.ncbi.nlm.nih.gov/pubmed/38924261
https://www.proquest.com/docview/3081484056
https://www.proquest.com/docview/3072799684
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIiEutLy3lJVBHDiQVeK8nPa0C10tIFCFtmgPSNHYsdWKNqma7AFu_PN6nActDwlxi-SJnNgz9jf2NzMALyxGV5kvpcel8L1I8dATGQZeVlhnJI65McqxLT4mi6Po3SpebcB-HwvT5ocYDtzIMtx6TQaOsr5i5MeoJ5QejwJ9iatFgOgTv3KD4OpqUgE6T_Ag6bIKEYtnePP6XvQbwLyOV92GM9-CL_2ntjyTr5N1Iyfq-y9ZHP_zX7bhTgdE2bTVnLuwoct7cOtDd9V-H360IbwuDIod67PqnI5ekM2Ywgsqc1fvsaOGmLXfWGUYHi6Xr1hbvYe9XbFTIiPVDMuCOR2rSehnc1MxF_rFPp80eHZSsvesL8fbdGL1A1jOD5avF15Xr8FTIa2bqsAYBaY6NpgagdIUqOJEWy0xWRhyQdnA0iBQPM0SLUyAfsF9HSZGmCiV4UPYLKtSPwaGvlFconUW0bqHfiqLVCQharRrRmExxwhe9hOXqy6XOZXUOM17n8aOaO5GdATPB9HzNoHHn4R2-9nPOxuu89Cipcj6v3EygmdDs7U-ulLBUldrkrH4z7qMIhrBo1Zrhl4sFCT8Qx_r5v7v3eeL6YF72Pl30Sdwm1t81TKHd2GzuVjrpxYfNXIMN3h0OIab09mb2XzszOISUJYMsQ
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwEB6VIgEXduiDAgZx4ECeEmdzql4KavVKFyGUondB0dix1aptUjV5B7j1n9fjLLQsEuIWyRM5sWfsb-yZ-QDeWoyuMl9Kj0vhe5HioScyDLystM5IHHNjlIu22E9mB9GneTxfgvUhF6arDzEeuJFluPWaDJwOpK9Y-SHqKdXHEzfgJjF6O4fqC79yh-CYNYmCzhM8SPq6QhTHM756fTf6DWJeR6xuy9m6B9-Gj-0iTY6ni1ZO1Y9f6jj-79_ch7s9FmUbnfI8gCVdPYRbe_1t-yO46LJ4XSYUO9Sn9RmdviD7wBSeE9Nds8YOWgqu_c5qw_Bznr9nHYEP256zE4pHahhWJXNq1pDQz-a2Zi77i309avH0qGI7bGDkbXux5jHkW5v5x5nXUzZ4KqSlU5UYo8BUxwZTI1CaElWcaKsoJgtDLqggWBoEiqdZooUJ0C-5r8PECBOlMnwCy1Vd6RVg6BvFJVp_Ea2H6KeyTEUSoka7bJQWdkzg3TBzherLmROrxkkxuDV2RAs3ohN4M4qedTU8_iS0Okx_0ZtxU4QWMEXWBY6TCbwem60B0q0KVrpekIyFgNZrFNEEnnZqM_Zi0SBBIPpYN_l_776YbWy6h2f_LvoKbs_yvd1id3t_5znc4RZudYHEq7Dcni_0CwuXWvnSWcUlSWUOgw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVcoLzahQIGceBAVonzcuip0K62FKoKbdEeKkVjx1Yr2mTVZA9w45_jcR60PCTELZIncmLP2N_YM98AvLQYXWW-lB6XwvcixUNPZBh4WWGdkTjmxigXbXGYTI-j9_N4vgLbfS5Myw8xHLiRZbj1mgx8UZgrRn6Kekz0eOIG3IwSX5BK737iV64QXGFNqkDnCR4kHa0QhfEMr17fjH5DmNcBq9txJnfgpP_WNtDky3jZyLH69guN43_-zDrc7pAo22lV5y6s6PIerH3s7trvw_c2h9flQbFTfVEt6OwF2Vum8JLq3NVv2HFDobVfWWUYHs1mr1lbvoftz9k5RSPVDMuCOSWrSehnc1Mxl_vFPp81eHFWsgPW1-NtOrH6Acwme7N3U68r2OCpkBZOVWCMAlMdG0yNQGkKVHGirZqYLAy5IDqwNAgUT7NECxOgX3Bfh4kRJkpl-BBWy6rUm8DQN4pLtN4iWv_QT2WRiiREjXbRKCzoGMGrfuJy1ZGZU02N87x3auyI5m5ER_BiEF20DB5_EtrqZz_vjLjOQwuXIusAx8kIng_N1vzoTgVLXS1JxgJA6zOKaAQbrdYMvVgsSACIPtbN_d-7z6c7e-7h0b-LPoO1o91J_mH_8OAx3OIWa7VRxFuw2lwu9ROLlRr51NnEDzDKDTs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identifying+hemophilia+B+carriers%3A+Utility+of+aPTT%2C+factor+IX+levels+and+ratios+of+factor+IX+to+other+Vitamin+K+dependent+factors&rft.jtitle=Haemophilia+%3A+the+official+journal+of+the+World+Federation+of+Hemophilia&rft.au=Shu%2C+Michael&rft.au=Malcolmson%2C+Caroline&rft.au=Bosch%2C+Alessandra&rft.au=Markovic%2C+Teodora&rft.date=2024-07-01&rft.eissn=1365-2516&rft_id=info:doi/10.1111%2Fhae.15068&rft_id=info%3Apmid%2F38924261&rft.externalDocID=38924261
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-8216&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-8216&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-8216&client=summon